References
- Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines
for the diagnosis and management of aspergillosis: 2016 update by the
Infectious Diseases Society of America. Clin Infect Dis. Clin Infect
Dis. 2016; 63(4): e1-e60.
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, et al. Clinical
Pharmacogenetics Implementation Consortium (CPIC) Guidelines for
CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2017; 102(1):
45-51.
- Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, et al. Clinical
practice guidelines for the management of candidiasis: 2009 update by
the Infectious Diseases Society of America. Clin Infect Dis. 2009;
48(5): 503-35.
- Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the
treatment of invasive candidiasis, aspergillosis and mucormycosis in
leukemia and hematopoietic stem cell transplant patients.
Haematologica. 2017; 102(3): 433-444.
- Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and
management of Aspergillus diseases: executive summary of the 2017
ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24: e1-e38.
- Zeng Y, Dai Y, Zhou Z, Yu X, Shi D. Hepatotoxicity-Related Adverse
Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal
Mining and Analysis of the FDA Adverse Event Report System Database.
Front Med (Lausanne). 2021; 8: 648164.
- Guo M, Liang J, Li D, Zhao Y, Xu W, Wang L, Cui X. Coagulation
dysfunction events associated with tigecycline: a real-world study
from FDA adverse event reporting system (FAERS) database. Thromb J.
2022; 20(1):12.
- US Food and Drug Administration. FDA Adverse Event Reporting System
(FAERS). Available online at:
https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
- Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its
advantages over the proportional reporting ratio. Pharmacoepidemiol
Drug Saf. 2004; 13(8): 519-23.
- Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR
reporting. Pharmacoepidemiol Drug Saf. 2009; 18:427–36.
- Panackal AA. Combination Antifungal Therapy for Invasive Aspergillosis
Revisited. Med Mycol Open Access. 2016; 2(2): 12-16.
- Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely
OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz
WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison
VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM,
Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Isavuconazole versus
voriconazole for primary treatment of invasive mould disease caused by
Aspergillus and other filamentous fungi (SECURE): a phase 3,
randomised-controlled, non-inferiority trial. Lancet. 2016;
387(10020): 760-769.
- Solís-Muñoz P, López JC, Bernal W, Willars C, Verma A, Heneghan MA,
Wendon J, Auzinger G. Voriconazole hepatotoxicity in severe liver
dysfunction. J Infect. 2013; 66(1): 80-86.
- Vena A, Bouza E, Bassetti M, Menichetti F, Merelli M, Grau S, Fortun
J, Sánchez MI, Aguado JM, Merino P, Bonache F, Muñoz P. Comparison of
the Safety and Tolerance Profile of Micafungin with that of Other
Echinocandins and Azoles in Patients with Pre-existing Child-Pugh B or
C Liver Disease: A Case-Control Retrospective Study. Infect Dis Ther.
2020; 9(1): 151-163.
- Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Adverse Effects
Associated with Currently Commonly Used Antifungal Agents: A Network
Meta-Analysis and Systematic Review. Front Pharmacol. 2021; 12:
697330.
- Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver
injury associated with antimycotics: Concise literature review and
clues from data mining of the FAERS database. World J Hepatol. 2014;
6(8): 601-612.
- Zhou ZX, Yin XD, Zhang Y, Shao QH, Mao XY, Hu WJ, Shen YL, Zhao B, Li
ZL. Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study
Leveraging the FDA Adverse Event Reporting System Database. Front
Pharmacol. 2022; 13: 891336.
- Douglas AP, Smibert OC, Bajel A, Halliday CL, Lavee O, McMullan B,
Yong MK, van Hal SJ, Chen SC; Australasian Antifungal Guidelines
Steering Committee. Consensus guidelines for the diagnosis and
management of invasive aspergillosis, 2021. Intern Med J. 2021; 51:
143-176.
- Almudena Martín-Peña, Manuela Aguilar-Guisado, Ildefonso Espigado,
José Miguel Cisneros, Antifungal Combination Therapy for Invasive
Aspergillosis. Clin Infect Dis. 2014; 59(10): 1437-1445.
- Teng GJ, Bai XR, Zhang L, Liu HJ, Nie XH. Remission of hepatotoxicity
in chronic pulmonary aspergillosis patients after lowering trough
concentration of voriconazole. World J Clin Cases. 2020; 8(20):
4700-4707.
- Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and
CYP2C19 polymorphism for optimised dosage regimens in patients with
invasive fungal infections. Int J Antimicrob Agents. 2014; 44(5):
436-442.
- Yamada T, Imai S, Koshizuka Y, Tazawa Y, Kagami K, Tomiyama N,
Sugawara R, Yamagami A, Shimamura T, Iseki K. Necessity for a
Significant Maintenance Dosage Reduction of Voriconazole in Patients
with Severe Liver Cirrhosis (Child-Pugh Class C). Biol Pharm Bull.
2018; 41(7): 1112-1118.
- Wang T, Yan M, Tang D, Xue L, Zhang T, Dong Y, Zhu L, Wang X, Dong Y.
A retrospective, multicenter study of voriconazole trough
concentrations and safety in patients with Child-Pugh class C
cirrhosis. J Clin Pharm Ther. 2018; 43(6): 849-854.